Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
FINASTERIDE
ACCORD HEALTHCARE INC
G04CB01
FINASTERIDE
5MG
TABLET
FINASTERIDE 5MG
ORAL
30/100/500
Prescription
5 ALFA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0124110001; AHFS:
APPROVED
2010-08-03
PRODUCT MONOGRAPH PR ACH-FINASTERIDE Finasteride Film-coated Tablets 5 mg Type II 5α-reductase inhibitor Accord Healthcare Inc. Date of revision: 3535 boul. St-Charles, Suite 704 December 10, 2019 Kirkland, QC, H9H 5B9 Canada SUBMISSION CONTROL NO: 234075 _ ACH-FINASTERIDE (finasteride)_ _Page 2 of 31_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE ....................................................................................... 3 CONTRAINDICATIONS............................................................................................................ 3 WARNINGS AND PRECAUTIONS ........................................................................................... 4 ADVERSE REACTIONS ............................................................................................................ 5 DRUG INTERACTIONS ............................................................................................................ 9 DOSAGE AND ADMINISTRATION ......................................................................................... 9 OVERDOSAGE ........................................................................................................................ 10 ACTION AND CLINICAL PHARMACOLOGY ...................................................................... 10 STORAGE AND STABILITY .................................................................................................. 11 SPECIAL HANDLING INSTRUCTIONS................................................................................. 11 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................... 11 PART II: SCIENTIFIC INFORMATION ................................................................................. 12 PHARMACEUTICAL INFORMATION ............................................. Baca dokumen lengkap